Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence.

Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, Capaldo BD, Guo F, Liu KH, Rios AC, Lim N, Kueh AJ, Virshup DM, Herold MJ, Tucker HO, Smyth GK, Lindeman GJ, Visvader JE.

Dev Cell. 2018 Dec 3;47(5):629-644.e8. doi: 10.1016/j.devcel.2018.10.001. Epub 2018 Oct 25.

PMID:
30523786
2.

A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer.

Lindeman GJ, Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Zivanovic Bujak A, Dawson SJ, Gray DHD, Visvader JE.

Cancer Discov. 2018 Dec 5. pii: CD-18-1151. doi: 10.1158/2159-8290.CD-18-1151. [Epub ahead of print]

PMID:
30518523
3.

Differential methylation analysis of reduced representation bisulfite sequencing experiments using edgeR.

Chen Y, Pal B, Visvader JE, Smyth GK.

Version 2. F1000Res. 2017 Nov 28 [revised 2018 Jan 1];6:2055. doi: 10.12688/f1000research.13196.2. eCollection 2017.

4.

Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids.

Michalak EM, Milevskiy MJG, Joyce RM, Dekkers JF, Jamieson PR, Pal B, Dawson CA, Hu Y, Orkin SH, Alexander WS, Lindeman GJ, Smyth GK, Visvader JE.

PLoS Biol. 2018 Aug 6;16(8):e2004986. doi: 10.1371/journal.pbio.2004986. eCollection 2018 Aug.

5.

Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling.

Pal B, Chen Y, Vaillant F, Jamieson P, Gordon L, Rios AC, Wilcox S, Fu N, Liu KH, Jackling FC, Davis MJ, Lindeman GJ, Smyth GK, Visvader JE.

Nat Commun. 2017 Nov 20;8(1):1627. doi: 10.1038/s41467-017-01560-x.

6.

A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice.

Jain R, Sheridan JM, Policheni A, Heinlein M, Gandolfo LC, Dewson G, Smyth GK, Sansom SN, Fu NY, Visvader JE, Holländer GA, Strasser A, Gray DHD.

Blood. 2017 Dec 7;130(23):2504-2515. doi: 10.1182/blood-2017-03-771576. Epub 2017 Sep 29.

7.

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.

PMID:
28768804
8.

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.

9.

RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Nolan E, Vaillant F, Visvader JE, Lindeman GJ.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038. No abstract available.

PMID:
28383640
10.

Elf5 is a principal cell lineage specific transcription factor in the kidney that contributes to Aqp2 and Avpr2 gene expression.

Grassmeyer J, Mukherjee M, deRiso J, Hettinger C, Bailey M, Sinha S, Visvader JE, Zhao H, Fogarty E, Surendran K.

Dev Biol. 2017 Apr 1;424(1):77-89. doi: 10.1016/j.ydbio.2017.02.007. Epub 2017 Feb 17.

11.

Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive.

Fu NY, Rios AC, Pal B, Law CW, Jamieson P, Liu R, Vaillant F, Jackling F, Liu KH, Smyth GK, Lindeman GJ, Ritchie ME, Visvader JE.

Nat Cell Biol. 2017 Mar;19(3):164-176. doi: 10.1038/ncb3471. Epub 2017 Feb 13.

PMID:
28192422
12.

Out-RANKing BRCA1 in Mutation Carriers.

Nolan E, Lindeman GJ, Visvader JE.

Cancer Res. 2017 Feb 1;77(3):595-600. doi: 10.1158/0008-5472.CAN-16-2025. Epub 2017 Jan 19. Review.

13.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

14.

New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells.

O'Brien CM, Chy HS, Zhou Q, Blumenfeld S, Lambshead JW, Liu X, Kie J, Capaldo BD, Chung TL, Adams TE, Phan T, Bentley JD, McKinstry WJ, Oliva K, McMurrick PJ, Wang YC, Rossello FJ, Lindeman GJ, Chen D, Jarde T, Clark AT, Abud HE, Visvader JE, Nefzger CM, Polo JM, Loring JF, Laslett AL.

Stem Cells. 2017 Mar;35(3):626-640. doi: 10.1002/stem.2558. Epub 2017 Jan 19.

15.

Derivation of a robust mouse mammary organoid system for studying tissue dynamics.

Jamieson PR, Dekkers JF, Rios AC, Fu NY, Lindeman GJ, Visvader JE.

Development. 2017 Mar 15;144(6):1065-1071. doi: 10.1242/dev.145045. Epub 2016 Dec 19.

16.

The complexities and caveats of lineage tracing in the mammary gland.

Rios AC, Fu NY, Cursons J, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2016 Nov 25;18(1):116.

17.

Lineage Tracing of Mammary Stem and Progenitor Cells.

van de Moosdijk AA, Fu NY, Rios AC, Visvader JE, van Amerongen R.

Methods Mol Biol. 2017;1501:291-308.

PMID:
27796960
18.

Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

Michalak EM, Visvader JE.

Mol Oncol. 2016 Dec;10(10):1497-1515. doi: 10.1016/j.molonc.2016.09.003. Epub 2016 Sep 23. Review.

19.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ.

Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.

PMID:
27322743
20.

Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.

Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA.

Cell Stem Cell. 2016 Jul 7;19(1):52-65. doi: 10.1016/j.stem.2016.05.003. Epub 2016 Jun 9.

21.

RUNX2 Mediates Plasmacytoid Dendritic Cell Egress from the Bone Marrow and Controls Viral Immunity.

Chopin M, Preston SP, Lun ATL, Tellier J, Smyth GK, Pellegrini M, Belz GT, Corcoran LM, Visvader JE, Wu L, Nutt SL.

Cell Rep. 2016 Apr 26;15(4):866-878. doi: 10.1016/j.celrep.2016.03.066. Epub 2016 Apr 14.

22.

Essential role for a novel population of binucleated mammary epithelial cells in lactation.

Rios AC, Fu NY, Jamieson PR, Pal B, Whitehead L, Nicholas KR, Lindeman GJ, Visvader JE.

Nat Commun. 2016 Apr 22;7:11400. doi: 10.1038/ncomms11400.

23.

Tissue-specific designs of stem cell hierarchies.

Visvader JE, Clevers H.

Nat Cell Biol. 2016 Apr;18(4):349-55. doi: 10.1038/ncb3332. Epub 2016 Mar 21.

PMID:
26999737
24.

Cellular Mechanisms Underlying Intertumoral Heterogeneity.

Sutherland KD, Visvader JE.

Trends Cancer. 2015 Sep;1(1):15-23. doi: 10.1016/j.trecan.2015.07.003. Epub 2015 Sep 28. Review.

PMID:
28741558
25.

Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Merino D, Lok SW, Visvader JE, Lindeman GJ.

Oncogene. 2016 Apr 14;35(15):1877-87. doi: 10.1038/onc.2015.287. Epub 2015 Aug 10. Review.

PMID:
26257067
26.

Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.

Pal B, Chen Y, Bert A, Hu Y, Sheridan JM, Beck T, Shi W, Satterley K, Jamieson P, Goodall GJ, Lindeman GJ, Smyth GK, Visvader JE.

Breast Cancer Res. 2015 Jun 18;17:85. doi: 10.1186/s13058-015-0585-0.

27.

Recruitment and activation of SLK at the leading edge of migrating cells requires Src family kinase activity and the LIM-only protein 4.

Baron KD, Al-Zahrani K, Conway J, Labrèche C, Storbeck CJ, Visvader JE, Sabourin LA.

Biochim Biophys Acta. 2015 Jul;1853(7):1683-92. doi: 10.1016/j.bbamcr.2015.04.003. Epub 2015 Apr 14. Erratum in: Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2754.

28.

A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1.

Sheridan JM, Ritchie ME, Best SA, Jiang K, Beck TJ, Vaillant F, Liu K, Dickins RA, Smyth GK, Lindeman GJ, Visvader JE.

BMC Cancer. 2015 Apr 3;15:221. doi: 10.1186/s12885-015-1187-z.

29.

Patient-derived xenograft models of breast cancer and their predictive power.

Whittle JR, Lewis MT, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2015 Feb 10;17:17. doi: 10.1186/s13058-015-0523-1. Review.

30.

EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival.

Fu NY, Rios AC, Pal B, Soetanto R, Lun AT, Liu K, Beck T, Best SA, Vaillant F, Bouillet P, Strasser A, Preiss T, Smyth GK, Lindeman GJ, Visvader JE.

Nat Cell Biol. 2015 Apr;17(4):365-75. doi: 10.1038/ncb3117. Epub 2015 Mar 2.

PMID:
25730472
31.

Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2.

Merino D, Best SA, Asselin-Labat ML, Vaillant F, Pal B, Dickins RA, Anderson RL, Strasser A, Bouillet P, Lindeman GJ, Visvader JE.

Oncogene. 2015 Jul 23;34(30):3926-34. doi: 10.1038/onc.2014.313. Epub 2014 Sep 29.

PMID:
25263453
32.

Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary.

Best SA, Hutt KJ, Fu NY, Vaillant F, Liew SH, Hartley L, Scott CL, Lindeman GJ, Visvader JE.

Development. 2014 Aug;141(16):3159-64. doi: 10.1242/dev.108498. Epub 2014 Jul 18.

33.

Mammary stem cells and the differentiation hierarchy: current status and perspectives.

Visvader JE, Stingl J.

Genes Dev. 2014 Jun 1;28(11):1143-58. doi: 10.1101/gad.242511.114. Review.

34.

Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland.

Godde NJ, Sheridan JM, Smith LK, Pearson HB, Britt KL, Galea RC, Yates LL, Visvader JE, Humbert PO.

PLoS Genet. 2014 May 22;10(5):e1004323. doi: 10.1371/journal.pgen.1004323. eCollection 2014 May.

35.

In situ identification of bipotent stem cells in the mammary gland.

Rios AC, Fu NY, Lindeman GJ, Visvader JE.

Nature. 2014 Feb 20;506(7488):322-7. doi: 10.1038/nature12948. Epub 2014 Jan 26.

PMID:
24463516
36.

The mammary stem cell hierarchy.

Fu N, Lindeman GJ, Visvader JE.

Curr Top Dev Biol. 2014;107:133-60. doi: 10.1016/B978-0-12-416022-4.00005-6. Review.

PMID:
24439805
37.

Distinct nuclear receptor expression in stroma adjacent to breast tumors.

Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL, Clyne CD.

Breast Cancer Res Treat. 2013 Nov;142(1):211-23.

PMID:
24122391
38.

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ.

Cancer Cell. 2013 Jul 8;24(1):120-9. doi: 10.1016/j.ccr.2013.06.002.

39.

Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2.

Pal B, Bouras T, Shi W, Vaillant F, Sheridan JM, Fu N, Breslin K, Jiang K, Ritchie ME, Young M, Lindeman GJ, Smyth GK, Visvader JE.

Cell Rep. 2013 Feb 21;3(2):411-26. doi: 10.1016/j.celrep.2012.12.020. Epub 2013 Jan 31.

40.

Structural basis of the interaction of the breast cancer oncogene LMO4 with the tumour suppressor CtIP/RBBP8.

Stokes PH, Liew CW, Kwan AH, Foo P, Barker HE, Djamirze A, O'Reilly V, Visvader JE, Mackay JP, Matthews JM.

J Mol Biol. 2013 Apr 12;425(7):1101-10. doi: 10.1016/j.jmb.2013.01.017. Epub 2013 Jan 23.

PMID:
23353824
41.

Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli.

Betterman KL, Paquet-Fifield S, Asselin-Labat ML, Visvader JE, Butler LM, Stacker SA, Achen MG, Harvey NL.

Am J Pathol. 2012 Dec;181(6):2225-38. doi: 10.1016/j.ajpath.2012.08.035. Epub 2012 Oct 11.

PMID:
23063660
42.

Cancer stem cells: current status and evolving complexities.

Visvader JE, Lindeman GJ.

Cell Stem Cell. 2012 Jun 14;10(6):717-728. doi: 10.1016/j.stem.2012.05.007. Review.

43.

Isolation of mouse mammary epithelial subpopulations: a comparison of leading methods.

Smalley MJ, Kendrick H, Sheridan JM, Regan JL, Prater MD, Lindeman GJ, Watson CJ, Visvader JE, Stingl J.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):91-7. doi: 10.1007/s10911-012-9257-1. Epub 2012 May 30. Review.

PMID:
22644112
44.

Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidermal autoregulatory factor-1 (Deaf-1) gene knock-out mice.

Czesak M, Le François B, Millar AM, Deria M, Daigle M, Visvader JE, Anisman H, Albert PR.

J Biol Chem. 2012 Feb 24;287(9):6615-27. doi: 10.1074/jbc.M111.293027. Epub 2012 Jan 9.

45.

Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells.

Eirew P, Kannan N, Knapp DJ, Vaillant F, Emerman JT, Lindeman GJ, Visvader JE, Eaves CJ.

Stem Cells. 2012 Feb;30(2):344-8. doi: 10.1002/stem.1001.

46.

The unmasking of novel unipotent stem cells in the mammary gland.

Visvader JE, Lindeman GJ.

EMBO J. 2011 Nov 8;30(24):4858-9. doi: 10.1038/emboj.2011.415. No abstract available.

47.

Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.

Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE.

Mol Cell Biol. 2011 Nov;31(22):4609-22. doi: 10.1128/MCB.05766-11. Epub 2011 Sep 19.

48.

Proteomic profiling of secretome and adherent plasma membranes from distinct mammary epithelial cell subpopulations.

Ji H, Goode RJ, Vaillant F, Mathivanan S, Kapp EA, Mathias RA, Lindeman GJ, Visvader JE, Simpson RJ.

Proteomics. 2011 Oct;11(20):4029-39. doi: 10.1002/pmic.201100102. Epub 2011 Sep 8.

PMID:
21834135
49.

Lineage specific methylation of the Elf5 promoter in mammary epithelial cells.

Lee HJ, Hinshelwood RA, Bouras T, Gallego-Ortega D, Valdés-Mora F, Blazek K, Visvader JE, Clark SJ, Ormandy CJ.

Stem Cells. 2011 Oct;29(10):1611-9. doi: 10.1002/stem.706.

50.

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.

Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71. doi: 10.1073/pnas.1104778108. Epub 2011 Jul 18.

Supplemental Content

Loading ...
Support Center